GW Pharmaceuticals Plc (GWPH):企業の財務・戦略的SWOT分析

◆英語タイトル:GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH56947FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥56,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

GW Pharmaceuticals Plc (GWPH) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary plant-derived cannabinoid product platform. The company offers Sativex for the treatment of spasticity due to multiple sclerosis and Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also advancing its pipeline for treatment of Rett syndrome, spasticity associated with spinal cord injury, post-traumatic stress disorder, schizophrenia, epilepsy, and neonatal hypoxic-ischemic encephalopathy. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridge, the UK.

GW Pharmaceuticals Plc Key Recent Developments

Apr 13,2021: GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting
Feb 16,2021: GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
Jan 11,2021: GW Pharmaceuticals provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
Nov 03,2020: GW Pharmaceuticals reports third quarter 2020 financial results and operational progress
Oct 21,2020: Greenwich Biosciences a subsidiary of GW Pharmaceuticals launches unspoken symphony, a breakthrough innovation created for the us epilepsy community

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
GW Pharmaceuticals Plc – Key Facts
GW Pharmaceuticals Plc – Key Employees
GW Pharmaceuticals Plc – Key Employee Biographies
GW Pharmaceuticals Plc – Major Products and Services
GW Pharmaceuticals Plc – History
GW Pharmaceuticals Plc – Company Statement
GW Pharmaceuticals Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
GW Pharmaceuticals Plc – Business Description
Product Category: Product Net Sales
Performance
Product Category: Other Revenue
Performance
Geographical Segment: Europe (Excluding the UK)
Performance
Geographical Segment: Other
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
GW Pharmaceuticals Plc – Corporate Strategy
GW Pharmaceuticals Plc – SWOT Analysis
SWOT Analysis – Overview
GW Pharmaceuticals Plc – Strengths
GW Pharmaceuticals Plc – Weaknesses
GW Pharmaceuticals Plc – Opportunities
GW Pharmaceuticals Plc – Threats
GW Pharmaceuticals Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GW Pharmaceuticals Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 13, 2021: GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting
Feb 16, 2021: GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
Jan 11, 2021: GW Pharmaceuticals provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
Nov 03, 2020: GW Pharmaceuticals reports third quarter 2020 financial results and operational progress
Oct 21, 2020: Greenwich Biosciences a subsidiary of GW Pharmaceuticals launches unspoken symphony, a breakthrough innovation created for the us epilepsy community
Sep 10, 2020: GW Pharmaceuticals announces the appointment of David Gryska to its Board of Directors
Aug 06, 2020: GW Pharmaceuticals reports second quarter 2020 financial results and operational progress
May 11, 2020: GW Pharmaceuticals reports first quarter 2020 financial results and operational progress
Feb 25, 2020: GW Pharmaceuticals reports fourth quarter and year-end 2019 financial results and operational progress
Jan 12, 2020: GW Pharmaceuticals pre-announces preliminary unaudited fourth quarter and full-year 2019 net product sales
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
GW Pharmaceuticals Plc, Key Facts
GW Pharmaceuticals Plc, Key Employees
GW Pharmaceuticals Plc, Key Employee Biographies
GW Pharmaceuticals Plc, Major Products and Services
GW Pharmaceuticals Plc, History
GW Pharmaceuticals Plc, Other Locations
GW Pharmaceuticals Plc, Subsidiaries
GW Pharmaceuticals Plc, Key Competitors
GW Pharmaceuticals Plc, Ratios based on current share price
GW Pharmaceuticals Plc, Annual Ratios
GW Pharmaceuticals Plc, Annual Ratios (Cont...1)
GW Pharmaceuticals Plc, Interim Ratios
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GW Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[GW Pharmaceuticals Plc (GWPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NARI Technology Development Co Ltd (600406):企業の財務・戦略的SWOT分析
    NARI Technology Development Co Ltd (600406) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析
    Summary Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a …
  • Polenergia SA (PEP):電力:M&Aディール及び事業提携情報
    Summary Polenergia SA (Polenergia) formerly Polish Energy Partners SA develops, implements and operates projects related to production of electricity and fuels. It offers services such as project implementation and supervision of construction, management of power facilities, production and sales of …
  • Paymark:企業の戦略的SWOT分析
    Paymark - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Suelopetrol CA SACA:企業の戦略的SWOT分析
    Suelopetrol CA SACA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • China Eastern Airlines Corporation Limited
    China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • GWA Group Limited (GWA):企業の財務・戦略的SWOT分析
    GWA Group Limited (GWA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Alamo Group, Inc.:企業の戦略・SWOT・財務情報
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ROHM Co Ltd (6963):企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Global Insurance Management Limited
    Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report Summary Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Pegasystems Inc (PEGA):企業の財務・戦略的SWOT分析
    Pegasystems Inc (PEGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Brighthouse Financial, Inc. (BHF):企業の財務・戦略的SWOT分析
    Brighthouse Financial, Inc. (BHF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Air Products and Chemicals Inc (APD)-石油・ガス分野:企業M&A・提携分析
    Summary Air Products and Chemicals Inc (Air Products) is an industrial gases company. It provides a portfolio of products, services, and solutions that include atmospheric, process and specialty gases, electronics and performance materials, and equipment. The company supplies oxygen, nitrogen, argon …
  • LGC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary LGC Ltd (LGC), formerly LGC (Teddington) Ltd is a life sciences measurement and testing company that offers reference materials, genomics solutions and analytical testing products and services. The company’s products comprise DNA extraction instrumentation, DNA extraction kits, Douglas scien …
  • Anaconda Mining Inc:企業の戦略・SWOT・財務情報
    Anaconda Mining Inc - Strategy, SWOT and Corporate Finance Report Summary Anaconda Mining Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Edwards Lifesciences Corp (EW):企業の財務・戦略的SWOT分析
    Edwards Lifesciences Corp (EW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Kirayaka Bank, Ltd.:企業の戦略・SWOT・財務情報
    Kirayaka Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kirayaka Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fuji Electric Co Ltd (6504):企業の財務・戦略的SWOT分析
    Fuji Electric Co Ltd (6504) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Dil Ltd (506414):企業の財務・戦略的SWOT分析
    Summary Dil Ltd (Dil), formerly Duphar-Interfran Ltd, is a developer of medicinal and pharmaceutical products. The company offers products in the areas such as biotechnology, environmental solutions, pharmaceuticals, and vitamins. It also offers services such as health and wellness, entertainment, e …
  • Rumex International Co:製品パイプライン分析
    Summary Rumex International Co (Rumex International) is a medical device company that manufactures and markets precision instruments for ophthalmology and cardiovascular surgery. The company provides products, which include blade holders, forceps, glaucoma instruments, hooks, lasik and lasek instrum …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆